TITLE

Endothelial cell injury by high glucose and heparanase is prevented by insulin, heparin and basic fibroblast growth factor

AUTHOR(S)
Juying Han; Mandal, Anil K.; Hiebert, Linda M.
PUB. DATE
January 2005
SOURCE
Cardiovascular Diabetology;2005, Vol. 4, p12
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Uncontrolled hyperglycemia is the main risk factor in the development of diabetic vascular complications. The endothelial cells are the first cells targeted by hyperglycemia. The mechanism of endothelial injury by high glucose is still poorly understood. Heparanase production, induced by hyperglycemia, and subsequent degradation of heparan sulfate may contribute to endothelial injury. Little is known about endothelial injury by heparanase and possible means of preventing this injury. Objectives: To determine if high glucose as well as heparanase cause endothelial cell injury and if insulin, heparin and bFGF protect cells from this injury. Methods: Cultured porcine aortic endothelial cells were treated with high glucose (30 mM) and/or insulin (1 U/ml) and/or heparin (0.5 μg/ml) and /or basic fibroblast growth factor (bFGF) (1 ng/ml) for seven days. Cells were also treated with heparinase I (0.3 U/ml, the in vitro surrogate heparanase), plus insulin, heparin and bFGF for two days in serum free medium. Endothelial cell injury was evaluated by determining the number of live cells per culture and lactate dehydrogenase (LDH) release into medium expressed as percentage of control. Results: A significant decrease in live cell number and increase in LDH release was found in endothelial cells treated with high glucose or heparinase I. Insulin and/or heparin and/or bFGF prevented these changes and thus protected cells from injury by high glucose or heparinase I. The protective ability of heparin and bFGF alone or in combination was more evident in cells damaged with heparinase I than high glucose. Conclusion: Endothelial cells injured by high glucose or heparinase I are protected by a combination of insulin, heparin and bFGF, although protection by heparin and/or bFGF was variable.
ACCESSION #
28682779

 

Related Articles

  • INTEGRATED PHYSIOLOGY--REGULATION OF GLUCOSE KINETICS.  // Diabetes;Jun2008 Supplement 1, Vol. 57, pA723 

    The article offers information on different studies on diabetes with topics about a computational model of hepatic glucose metabolism, assessing insulin sensitivity in mice, lipoprotein lipase mass in pre-heparin serum, and homeostasis model assessment. The study on the computational model shows...

  • Does the Simultaneous Use of Selenium and Vitamin E Improve Type 2 Diabetes Status? Farrag, Ebtehal K.; Metwally, Nadia S.; Maghraby, Amany S.; Mourad, Iman M.; Foda, Doaa S.; Rawi, Sayed M. // International Journal of Pharmaceutical Sciences Review & Resear;May/Jun2014, Vol. 26 Issue 2, p129 

    The aim of the present work was to investigate whether the antioxidant selenium (Se) and vitamin E (Vit E) treatment would impact on the onset of diabetes, compared to the currently available antidiabetic drug amaryl. We examined some biochemical parameters in serum including glucose, insulin,...

  • Defining the Role of Repaglinide in the Management of Type 2 Diabetes Mellitus: A Review. Johansen, Odd Erik; Birkeland, Kåre I // American Journal of Cardiovascular Drugs;2007, Vol. 7 Issue 4, p319 

    Type 2 diabetes mellitus (T2DM) is characterized by hyperglycemia due to a combination of insulin resistance and impaired insulin secretion. The hyperglycemia is associated with an increased risk for micro- and macrovascular complications, and lowering fasting and postprandial hyperglycemia may...

  • Type-1 diabetes. Kumar, Senthil; Bain, Steve C. // GP: General Practitioner;10/24/2008, p29 

    The article offers a clinical review and information on type-1 diabetes. Type-1 diabetes or diabetes mellitus is a clinical syndrome distinguishable by hyperglycaemia. It can be diagnosed at any age and there is increasing recognition that patients labeled as having type-2 diabetes have a slowly...

  • Pharmacotherapy for Hyperglycemia in Noncritically Ill Hospitalized Patients. Mendez, Carlos E.; Umpierrez, Guillermo E. // Diabetes Spectrum;Summer2014, Vol. 27 Issue 3, p180 

    Hyperglycemia in the hospital setting affects 38–46% of noncritically ill hospitalized patients. Evidence from observational studies indicates that inpatient hyperglycemia, in patients with and without diabetes, is associated with increased risks of complications and mortality....

  • Troglitazone prevents hyperglycemia-induced but not glucosamine-induced insulin resistance. Miles, Philip D.G.; Higo, Katsuya; Romeo, Oreste M.; Lee, Moon-Kyu; Rafaat, Karim; Olefsky, Jerrold M. // Diabetes;Mar1998, Vol. 47 Issue 3, p395 

    Investigates the effect of troglitazone on insulin action in rats made hyperglycemic or infused with glucosamine to determine whether the drug could prevent the development of hyperglycemia-induced insulin resistance. Troglitazone as an orally active hypoglycemic agent; Infusion of glucose and...

  • A Target Based Therapeutic Approach Towards Diabetes Mellitus Using Medicinal Plants. Prabhakar, Pranav K.; Doble, Mukesh // Current Diabetes Reviews;2008, Vol. 4 Issue 4, p291 

    Diabetes mellitus (DM) is not one disease but is a heterogonous group of syndromes. Contrary to the popular belief DM is a metabolic disorder characterized by increased blood glucose level (hyperglycemia) and this is because of insufficient or inefficient insulin secretary response. Glucose is...

  • 5-Aminoimidazole-4-Carboxamide-1-β-D-Ribofuranoside Causes Acute Hepatic Insulin Resistance In Vivo. Pencek, R. Richard; Shearer, Jane; Camacho, Raul C.; James, Freyja D.; Lacy, D. Brooks; Fueger, Patrick T.; Donahue, E. Patrick; Snead, Wanda; Wasserman, David H. // Diabetes;Feb2005, Vol. 54 Issue 2, p355 

    The infusion of 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) causes a rise in tissue concentrations of the AMP analog 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranotide (ZMP), which mimics an elevation of cellular AMP levels. The purpose of this work was to determine the...

  • Action mechanism of metallo-allixin complexes as antidiabetic agents. Hiromura, Makoto; Sakurai, Hiromu // Pure & Applied Chemistry;Dec2008, Vol. 80 Issue 12, p2727 

    The metabolic syndrome is a group of factors associated with an increased risk of atherosclerosis and diabetes. Diabetes mellitus (DM) is classified into 2 major types—type 1 DM and type 2 DM—characterized by chronic hyperglycemia resulting from defects in insulin secretion and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics